drugset / Trial / NCT04461483

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

NCT04461483

Phase 1 Completed 33 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-935 with single ascending doses (Part 1) and multiple doses with titration (Part 2).

Timeline

Start
2020-08-13
Primary completion
2020-11-14
Completion
2020-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Soticlestat Small molecule 200 mg Oral
Subject Soticlestat Small molecule 300 mg Oral
Subject Soticlestat Small molecule 600 mg Oral
Subject Soticlestat Small molecule 1200 mg Oral

Indications

No indication recorded.